BPM’s DNlite-IVD103 Secures Regulatory Approval in Singapore

A study by the Saw Swee Hock School of Public Health at the National University of Singapore predicts that the number of diabetic adults in the city-state will reach 1 million by 2050 (a 40% increase from 2021), with annual economic costs projected at $1.867 billion USD. In response, the Singaporean government has been exceptionally proactive. Since declaring a "War on Diabetes" in 2016, authorities have launched aggressive health initiatives, including the world’s first ban on advertisements for high-sugar beverages and the mandatory "Nutri-Grade" labeling system.

Riding the "CKD Tsunami" with Precision Medicine

Dr. Tseng further noted that the local medical community has described the escalating crisis as a "CKD Tsunami." This heightened focus on DKD prevention and co-management creates a definitive market opportunity for DNlite-IVD103. "Our next step is to aggressively establish local marketing channels and work with distributors to integrate DNlite-IVD103 into the government's health insurance and reimbursement systems," said Dr. Tseng. "Our goal is to see DNlite-IVD103 adopted into national clinical guidelines and eventually established as a routine diagnostic standard." BPM remains committed to pursuing further regulatory certifications in other ASEAN countries to deepen its regional footprint and provide life-saving early detection to patients worldwide.

Related Links:

新穎生醫創新檢測試劑獲新加坡查驗許可 前進東協市場  科技島

東協市場再下一城 新穎生醫DNlite-IVD103獲星上市許可 時報

新穎生醫東協邁步 DNlite-IVD103獲星國上市許可 MoneyDJ

新穎檢測試劑 獲新加坡上市許可 工商時報

東協市場再報捷！新穎DNlite-IVD103獲星國上市許可 工商時報 

新穎生醫糖尿病腎病變檢測DNlite-IVD103獲新加坡上市許可 環球生技